Axial spondyloarthritis (axSpA), comprising ankylosing spondylitis (AS) and nonradiographic axial SpA, is the main form of chronic inflammatory arthritis affecting the axial skeleton. The availability of new medications approved by the U.S. Food & Drug Administration to treat AS, as well as new evidence on tapering and discontinuing biologics, magnetic resonance imaging and radiograph imaging were the driving forces behind the release of a revised treatment guideline for AS and non-radiographic axial spondyloarthritis in 2019. In this resource center, you’ll find our summary of the guideline, as well as current research reviews, case reports and clinical articles on advances in the diagnosis and management of axial spondyloarthritis.
With ~100 research abstracts on axSpA accepted for presentation at ACR Convergence 2022, filtering the noise to get to the key thoughts may be challenging. Below, founding editor of The Rheumatologist, David S. Pisetsky, MD, PhD, offers his picks for the top research in axSpA that came out of the annual meeting.
FEATURED ARTICLE: Sacroiliitis on MRI: axSpA or Another Cause?
